StoxFortis Healthcare vs Gland Pharma: share price & financials comparison
NSE: FORTIS vs GLAND · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Fortis Healthcare vs Gland Pharma at a glance
Fortis Healthcare (FORTIS) has a market capitalisation of ₹57,898 Cr, against ₹52,281 Cr for Gland Pharma (GLAND). Over the past year Gland Pharma has returned +66.4%, compared with -27.3% for Fortis Healthcare. On valuation, Gland Pharma trades at a lower P/E of 46.3 versus 55.8. Gland Pharma earns a higher return on equity (10.9% vs 9.9%). Fortis Healthcare comes out ahead on size. Gland Pharma comes out ahead on valuation, profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Fortis Healthcare leads on 4 and Gland Pharma on 13. On StoxGud's 10-point checklist, Fortis Healthcare scores 4/10 and Gland Pharma scores 9/10.
| Metric | Fortis Healthcare | Gland Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹57,898 Cr | ₹52,281 Cr |
| Revenue (latest FY) | ₹9,128 Cr | ₹6,431 Cr |
| Net profit (latest FY) | ₹1,042 Cr | ₹1,027 Cr |
| Valuation | ||
| P/E | 55.8 | 46.3 |
| P/B | 5.53 | 5.05 |
| Dividend yield | 0.13% | 0.57% |
| Profitability | ||
| Return on equity | 9.9% | 10.9% |
| Net profit margin | 10.5% | 16.8% |
| Operating margin | 22.2% | 26.0% |
| Growth | ||
| Revenue growth (YoY) | +17.3% | +19.6% |
| Net profit growth (YoY) | -3.0% | +47.1% |
| Revenue CAGR (multi-year) | +17.8% | +13.2% |
| Financial health | ||
| Debt to equity | 0.30 | 0.02 |
| Momentum | ||
| 1-month return | -1.6% | +0.6% |
| 1-year return | -27.3% | +66.4% |
| 3-year CAGR | +32.0% | +26.2% |
| 5-year CAGR | +25.0% | -2.8% |
| 10-year CAGR | +16.3% | — |
| Distance from 52W high | -26.6% | +0.0% |
| Technicals | ||
| RSI (14) | 57 | 60 |
| Price vs 200-day avg | -14.2% | +37.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Fortis Healthcare | Gland Pharma |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 4/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Fortis Healthcare or Gland Pharma?
Fortis Healthcare has a market cap of ₹57,898 Cr and Gland Pharma has a market cap of ₹52,281 Cr as of 06 Nov 2026.
Which has a lower P/E, Fortis Healthcare or Gland Pharma?
Gland Pharma has the lower P/E: Fortis Healthcare trades at 55.8 and Gland Pharma at 46.3.
Which gave better returns in the last year, Fortis Healthcare or Gland Pharma?
Gland Pharma did better: Fortis Healthcare returned -27.3% and Gland Pharma returned +66.4% over one year.
Is Fortis Healthcare or Gland Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Fortis Healthcare scores 4/10 and Gland Pharma scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.